101
Views
6
CrossRef citations to date
0
Altmetric
Reviews

Biology of LOX-1 in relation to atherogenesis

& , MD, PhD
Pages 689-696 | Published online: 18 Jan 2017

Bibliography

  • Landmesser U, Hornig B, Drexler H:Endothelial function: a critical determinant inatherosclerosis? Circulation 109, II27–II33(2004).
  • Reviews new insights into mechanismsof endothelial dysfunction associatedwith atherosclerosis.
  • Virani SS, Polsani VR, Nambi V: Novelmarkers of infl ammation in atherosclerosis.Curr. Atheroscler. Rep. 10, 164–170 (2008)
  • Schulze PC, Lee RT: Oxidative stress andatherosclerosis. Curr. Atheroscler. Rep. 7,242–248 (2005)
  • McCord JM: Oxygen-derived radicals: a linkbetween reperfusion injury and infl ammation.Fed. Proc. 46, 2402–2406 (1987)
  • Matsuura E, Kobayashi K, Tabuchi M,Lopez LR: Oxidative modifi cation oflow-density lipoprotein and immune regulationof atherosclerosis. Prog. Lipid. Res. 45,466–486 (2006)
  • Mehta JL: Oxidized or native low-densitylipoprotein cholesterol: which is moreimportant in atherogenesis? J. Am. Coll.Cardiol. 48, 980–982 (2006)
  • Li D, Mehta JL: Antisense to LOX-1 inhibitsoxidized LDL-mediated upregulation ofmonocyte chemoattractant protein-1 andmonocyte adhesion to human coronary arteryendothelial cells. Circulation 101, 2889–2895(2000)
  • Li D, Chen H, Sawamura T, Saldeen T,Mehta JL: Statins modulate oxidizedlow-density lipoprotein-mediated adhesionmolecule expression in human coronary arteryendothelial cells: role of LOX-1. J. Pharmacol.Exp. Ther. 302, 601–605 (2002)
  • Erl W, Weber PC, Weber C: Monocytic celladhesion to endothelial cells stimulated byoxidized low-density lipoprotein is mediated bydistinct endothelial ligands. Atherosclerosis 136,297–303 (1998)
  • Li D, Liu L, Chen H, Sawamura T,Mehta JL: LOX-1, an oxidized LDLendothelial receptor, induces CD40/CD40Lsignaling in human coronary artery endothelialcells. Arterioscler. Thromb. Vasc. Biol. 23,816–821 (2003)
  • Li D, Liu L, Chen H, Sawamura T,Ranganathan S, Mehta JL: LOX-1 mediatesoxidized low-density lipoprotein-inducedexpression of matrix metalloproteinases inhuman coronary artery endothelial cells.Circulation 107, 612–617 (2003)
  • Chen K, Chen J, Liu Y et al.: Adhesionmolecule expression in fi broblasts: alteration infi broblast biology after transfection withLOX-1 plasmids. Hypertension 46, 622–627(2005)
  • Cominacini L, Pasini AF, Garbin U, Davoli A,Tosetti ML, Sawamura T:Oxidized low density lipoprotein(Ox-LDL ) binding to Ox-LDL receptor-1in endothelial cells induces the activation ofNF-κB through an increased productionof intracellular reactive oxygen species.J. Biol. Chem. 275, 12633–12638 (2000)
  • Chavakis E, Dernbach E, Dimmeler S:LDL oxidized inhibits vascular endothelialgrowth factor-induced endothelial cellmigration by an inhibitory effect on theAkt/endothelial nitric oxide synthase pathway.Circulation 103, 2102–2107(2001)
  • Dhaliwal BS, Steinbrecher UP: Scavengerreceptors and oxidized low densitylipoproteins. Clin. Chim. Acta. 286,191–205 (1999)
  • Sawamura T, Kume N, Aoyama T et al.:An endothelial receptor for oxidizedlow-density lipoprotein. Nature 386, 73–77(1997).
  • Identifi es lectin-like ox-LDL receptor-1(LOX-1), an endothelial receptor foroxidized LDL (ox-LDL).
  • Mehta JL, Li DY: Identifi cation andautoregulation of receptor for OX-LDL incultured human coronary artery endothelialcells. Biochem. Biophys. Res. Commun. 248,511–514 (1998)
  • Aoyama T, Fujiwara H, Masaki T,Sawamura T: Induction of lectin-likeoxidized LDL receptor by oxidized LDL andlysophosphatidylcholine in culturedendothelial cells. J. Mol. Cell. Cardiol.31, 2101–2114 (1999)
  • Bickel PE, Freeman M: Rabbit aortic smoothmuscle cells express inducible macrophagescavenger receptor messenger RNA that isabsent from endothelial cells. J. Clin. Invest.90, 1450–1457 (1992)
  • Mehta JL, Chen J, Hermonat PL, Romeo F,Novelli G: Lectin-like oxidized-low densitylipoprotein receptor-1 (LOX-1): a critical playerin the development of atherosclerosis andrelated disorders. Cardiovasc. Res. 69, 36–45(2006).
  • Detailed review summarizing the importantrole of LOX-1 in the genesisand development of atherosclerosis andrelated disorders.
  • Xu X, Gao X, Potter BJ, Cao JM, Zhang C:Anti-LOX-1 rescues endothelial function incoronary arterioles in atherosclerotic ApoEknockout mice. Arterioscler. Thromb. Vasc.Biol. 27, 871–877 (2007)
  • Mehta JL, Sanada N, Hu CP et al.:Deletion of LOX-1 reduces atherogenesisin LDLR knockout mice fed highcholesterol diet. Circ. Res. 100, 1634–1642(2007).
  • Demonstrates that LOX-1 deletion sustainsendothelial function in association with areduction in proinfl ammatory andpro-oxidant signals.
  • Li D, Saldeen T, Romeo F, Mehta JL:Oxidized LDL upregulates angiotensin IItype 1 receptor expression in culturedhuman coronary artery endothelial cells:the potential role of transcription factorNF-κB. Circulation 102, 1970–1976(2000)
  • Li D, Singh RM, Liu L et al.: Oxidized-LDLthrough LOX-1 increases the expression ofangiotensin converting enzyme in humancoronary artery endothelial cells. Cardiovasc.Res. 57, 238–243 (2003)
  • Schmieder RE, Hilgers KF, Schlaich MP,Schmidt BM: Renin–angiotensin system andcardiovascular risk. Lancet 369, 1208–1219(2007)
  • Draude G, Lorenz RL: The expression of thelectin-like oxidized low-density lipoproteinreceptor (LOX-1) on human vascular smoothmuscle cells and monocytes and its downregulationby lovastatin. Biochem. Pharmacol.57, 383–386 (1999)
  • Shin HK, Kim YK, Kim KY, Lee JH,Hong KW: Remnant lipoprotein particlesinduce apoptosis in endothelial cells byNAD(P)H oxidase-mediated production ofsuperoxide and cytokines via lectin-likeoxidized low-density lipoprotein receptor-1activation: prevention by cilostazol. Circulation109, 1022–1028 (2004)
  • Chen M, Kakutani M, Naruko T: Activationdependentsurface expression of LOX-1 inhuman platelets, Biochem. Biophys. Res.Commun. 282, 153–158 (2001)
  • Marwali MR, Hu CP, Mohandas B et al.:Modulation of ADP-induced platelet activationby aspirin and pravastatin: role of lectin-likeoxidized low-density lipoprotein receptor-1,nitric oxide, oxidative stress and inside-outintegrin signaling. J. Pharmacol. Exp. Ther. 322,1324–1332 (2007)
  • Chen K, Chen J, Li D, Zhang X, Mehta JL:Angiotensin II regulation of collagen type Iexpression in cardiac fi broblasts: modulation byPPAR-γ ligand pioglitazone. Hypertension 44,655–661 (2004)
  • Chen J, Liu Y, Liu H, Hermonat PL, Mehta JL:Molecular dissection of angiotensin II-activatedhuman LOX-1 promoter. Arterioscler. Thromb.Vasc. Biol.26, 1163–1168 (2006)
  • Sorescu D: Smad3 mediates angiotensin II- andTGF-β1-induced vascular fi brosis: Smad3thickens the plot. Circ. Res. 98, 988–989(2006)
  • Hu C, Dandapat A, Sun L et al.: Regulation ofTGFβ1-mediated collagen formation byLOX-1: studies based on forced overexpressionof TGFβ1 in wild-type and LOX-1 knockoutmouse cardiac fi broblasts. J. Biol. Chem. 283,10226–10231 (2008).
  • Demonstrates that collagen synthesis incardiac fi broblasts involves a facilitativeinteraction between TGF-β(1)-NADPHoxidase and LOX-1.
  • Clerk A, Sudden PH: Infl ame my heart (byp38-MAPK). Circ. Res. 99, 455–458 (2006)
  • Ishigaki Y, Katagiri H, Gao J et al.: Impact ofplasma oxidized low-density lipoproteinremoval on atherosclerosis. Circulation 118,75–83 (2008).
  • Demonstrates that LOX-1 expressedectopically in the liver with adenovirusadministration in ApoE-defi cient miceremoves ox-LDL from circulating blood,resulting in complete prevention ofatherosclerosis progression.
  • Inoue K, Arai Y, Kurihara H, Kita T, SawamuraT: Overexpression of lectin-like oxidizedlow-density lipoprotein receptor-1 inducesintramyocardial vasculopathy in apolipoproteinE-null mice. Circ. Res. 97, 176–184 (2005)
  • Jacob MP, Badier-Commander C, Fontaine V,Benazzoug Y, Feldman L, Michel JB:Extracellular matrix remodeling in the vascularwall. Pathol. Biol. 49, 326–332 (2001)
  • Cuaz-Pérolin C, Jguirim I, Lariqauderie Get al.: Apolipoprotein E knockout miceover-expressing human tissue inhibitor ofmetalloproteinase 1 are protected againstaneurysm formation but not againstatherosclerotic plaque development. J. Vasc.Res. 43, 493–501 (2006)
  • Shah PK: Pathophysiology of plaque ruptureand the concept of plaque stabilization.Cardiol. Clin. 14, 17–29 (1996)
  • Kunz J: Matrix metalloproteinases andatherogenesis in dependence of age.Gerontology 53, 63–73 (2007)
  • Rekhter MD: Collagen synthesis inatherosclerosis: too much and not enough.Cardiovasc. Res. 41, 376–384 (1999)
  • Hu CP, Dandapat A, Liu Y, Hermonat PL,Mehta JL: Blockade of hypoxia-reoxygenationmediatedcollagen type I expression and MMPactivity by over-expression of TGF-β1 in mousecardiomyocytes. Am. J. Physiol. Heart. Circ.Physiol. 293, H1833–H1838 (2007)
  • Hu C, Dandapat A, Chen J et al.: LOX-1deletion alters signals of myocardial remodelingimmediately after ischemia–reperfusion.Cardiovasc. Res. 76, 292–302 (2007)
  • Hu C, Dandapat A, Sun L et al.: Modulation ofangiotensin II-mediated hypertension andcardiac remodeling by lectin-like oxidizedlow-density lipoprotein receptor-1 deletion.Hypertension 52(3), 556–562 (2008)
  • Hu C, Dandapat A, Sun L et al.: LOX-1deletion decreases collagen accumulation inatherosclerotic plaque in low-density lipoproteinreceptor knockout mice fed a high-cholesteroldiet. Cardiovasc. Res. 79, 287–293 (2008).
  • Demonstrates that LOX-1 deletion reducesenhanced collagen deposition and matrixmetalloprotein expression in atheroscleroticregions via inhibition of pro-oxidant signals.
  • Ishino S, Mukai T, Kume N et al.: Lectin-likeoxidized LDL receptor-1 (LOX-1) expression isassociated with atherosclerotic plaque instability–ana lysis in hypercholesterolemic rabbits.Atherosclerosis 195, 48–56 (2007)
  • Saini HK, Xu YJ, Arneja AS, Tappia PS, DhallaNS: Pharmacological basis of different targetsfor the treatment of atherosclerosis. J. Cell. Mol.Med. 9, 818–839 (2005)
  • Böhm M: Angiotensin receptor blockers versusangiotensin-converting enzyme inhibitors:where do we stand now? Am. J. Cardiol. 100,38J–44J (2007)
  • Tenenbaum A, Fisman EZ, Motro M, Adler Y:Optimal management of combineddyslipidemia: what have we behind statinsmonotherapy? Adv. Cardiol. 45, 127–153(2008)
  • Tahara N, Kai H, Ishibashi M et al.:Simvastatin attenuates plaque infl ammation:evaluation by fl uorodeoxyglucose positronemission tomography. J. Am. Coll. Cardiol. 48,1825–1831 (2006)
  • Chen J, Li D, Schaefer R, Mehta JL: Cross-talkbetween dyslipidemia and renin-angiotensinsystem and the role of LOX-1 and MAPK inatherogenesis studies with the combined use ofrosuvastatin and candesartan. Atherosclerosis184, 295–301 (2006)
  • Kobayashi N, Honda T, Yoshida K et al.:Critical role of bradykinin-eNOS and oxidativestress-LOX-1 pathway in cardiovascularremodeling under chronic angiotensinconvertingenzyme inhibition. Atherosclerosis187, 92–100 (2006)
  • Libby P: Current concepts of the pathogenesisof the acute coronary syndromes. Circulation104, 365–372 (2001).
  • The most comprehensive and current reviewrelated to plaque vulnerability thatconceptualizes development ofanimal models.
  • Rekhter M: Vulnerable atherosclerotic plaque:emerging challenge for animal models. Curr.Opin. Cardiol. 17, 626–632 (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.